Literature DB >> 16981243

Renal prothrombin mRNA is significantly decreased in a hyperoxaluric rat model of nephrolithiasis.

P K Grover1, K Miyazawa, M Coleman, J Stahl, R L Ryall.   

Abstract

Although urinary prothrombin fragment 1 (UPTF1) possesses several hallmarks expected of a regulatory protein in urolithiasis, its precise role remains unknown. To determine the relationship between renal prothrombin (PT), the parent molecule of UPTF1, and lithogenesis, this study quantified and compared levels of renal PT mRNA in healthy rats (n = 10) and rats rendered lithogenic (n = 10) by ingestion of 0.75% ethylene glycol for 8 weeks. Studies included morphological and histological examination of the kidneys with scanning electron microscopy of the urinary filtrates of control and experimental animals. Haematuria and calcium oxalate (CaOx) crystals occurred in the urine of all experimental rats, but not in those of controls. Histological examination showed birefringent nephroliths and associated damage in kidneys of lithogenic rats, which were not seen in the control group. The amounts of total RNA extracted from both groups of rats were similar, but the median ratio of PT to beta-actin transcript of 11.14 x 10(-4) (10.65 x 10(-4) +/- 2.24 x 10(-4)) in the control rats was significantly (p < or = 0.001) reduced to 6.47 x 10(-4) (6.57 x 10(-4) +/- 2.72 x 10(-4)) in the lithogenic group. These results demonstrate that renal PT mRNA is reduced by approximately 42% in lithogenic rats and confirm the existence of a direct association between renal PT synthesis and calculogenesis. Attempts to compare renal PT and urinary levels of PTF1 were unsuccessful because of interference from hepatic PT circulating in the blood, haematuria, and the presence of urinary CaOx crystals. This is the first report of a significant reduction in the renal expression of a urinary protein well documented to inhibit CaOx crystal growth and aggregation in undiluted human urine in vitro. Copyright 2006 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16981243     DOI: 10.1002/path.2061

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  6 in total

1.  A comparison of the binding of urinary calcium oxalate monohydrate and dihydrate crystals to human kidney cells in urine.

Authors:  Tingting Wang; Lauren A Thurgood; Phulwinder K Grover; Rosemary L Ryall
Journal:  BJU Int       Date:  2010-12       Impact factor: 5.588

2.  Decreased expression of vitamin K epoxide reductase complex subunit 1 in kidney of patients with calcium oxalate urolithiasis.

Authors:  Bo Hu; Tao Wang; Zhuo Liu; Xiaolin Guo; Jun Yang; Jihong Liu; Shaogang Wang; Zhangqun Ye
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-12-16

3.  Regulation of macromolecular modulators of urinary stone formation by reactive oxygen species: transcriptional study in an animal model of hyperoxaluria.

Authors:  Saeed R Khan; Sunil Joshi; Wei Wang; Ammon B Peck
Journal:  Am J Physiol Renal Physiol       Date:  2014-03-05

4.  cDNA macroarray analysis of genes in renal epithelial cells exposed to calcium oxalate crystals.

Authors:  Katsuhito Miyazawa; Kinue Aihara; Ryosuke Ikeda; Manabu T Moriyama; Koji Suzuki
Journal:  Urol Res       Date:  2008-12-09

5.  Association between human prothrombin variant (T165M) and kidney stone disease.

Authors:  Nanyawan Rungroj; Nirinya Sudtachat; Choochai Nettuwakul; Nunghathai Sawasdee; Oranud Praditsap; Prapaporn Jungtrakoon; Suchai Sritippayawan; Duangporn Chuawattana; Sombat Borvornpadungkitti; Chagkrapan Predanon; Wattanachai Susaengrat; Pa-Thai Yenchitsomanus
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

6.  Diversity in protein profiles of individual calcium oxalate kidney stones.

Authors:  Nobuaki Okumura; Masao Tsujihata; Chikahiro Momohara; Iwao Yoshioka; Kouzou Suto; Norio Nonomura; Akihiko Okuyama; Toshifumi Takao
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.